within Pharmacolibrary.Drugs.S_SensoryOrgans.S01J_DiagnosticAgents.S01JA51_FluoresceinCombinations;

model FluoresceinCombinations
  extends Pharmacolibrary.Drugs.ATC.S.S01JA51;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01JA51</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fluorescein is a synthetic organic compound and fluorophore used as a diagnostic agent in ophthalmology for visualizing corneal abrasions, retinal blood flow, and other eye conditions. It is usually administered topically or intravenously. In combinations (ATC S01JA51), it is used for diagnostic purposes in combination with other agents such as local anaesthetics. Fluorescein is an approved drug and widely used in current clinical practice.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic (PK) data specific for fluorescein, combinations (ATC S01JA51) was found. PK parameters are estimated based on intravenous administration of fluorescein in healthy adults.</p><h4>References</h4><ol><li><p>Millul, J, et al., &amp; Cazzamalli, S (2021). An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications. <i>Proceedings of the National Academy of Sciences of the United States of America</i> 118(16) –. DOI:<a href=\"https://doi.org/10.1073/pnas.2101852118\">10.1073/pnas.2101852118</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33850024/\">https://pubmed.ncbi.nlm.nih.gov/33850024</a></p></li><li><p>Daniels, AB, et al., &amp; Friedman, DL (2021). Efficacy, Toxicity, and Pharmacokinetics of Intra-Arterial Chemotherapy Versus Intravenous Chemotherapy for Retinoblastoma in Animal Models and Patients. <i>Translational vision science &amp; technology</i> 10(11) 10–None. DOI:<a href=\"https://doi.org/10.1167/tvst.10.11.10\">10.1167/tvst.10.11.10</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34495330/\">https://pubmed.ncbi.nlm.nih.gov/34495330</a></p></li><li><p>Zeper, LW, et al., &amp; de Baaij, JHF (2024). Liver and spleen predominantly mediate calciprotein particle clearance in a rat model of chronic kidney disease. <i>American journal of physiology. Renal physiology</i> 326(4) F622–F634. DOI:<a href=\"https://doi.org/10.1152/ajprenal.00239.2023\">10.1152/ajprenal.00239.2023</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38420675/\">https://pubmed.ncbi.nlm.nih.gov/38420675</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end FluoresceinCombinations;
